Ophthalmology

This month-in-review features an exclusive interview with Srinivas R. Sadda, MD, and promising data from studies on geographic atrophy, diabetic macular ischemia, diabetic retinopathy, and AMD.

Cindy X. Cai, MD, describes how both place and individual-level factors are associated with lapses in diabetic retinopathy care.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

Deepak Sambhara, MD, describes the influence of baseline central retinal thickness on visual outcomes in a post-hoc analysis of the PHOTON study.

Aflibercept 8 mg exhibited clinically meaningful visual, anatomic improvements at Week 48 in patients with DME regardless of baseline visual acuity.

Pre-dose IOP outcomes in eyes with DME receiving intravitreal aflibercept 8 mg or 2 mg were comparable and remained stable through Week 48.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

Factors, including social deprivation and race, significantly affected visit adherence for patients with nAMD across a large healthcare system.

At ARVO 2024, Nazlee Zebardast, MD, MSc describes the value of a polygenic risk score to predict the onset of primary open-angle glaucoma.

A higher dietary intake of several nutrients was strongly associated with slower progression toward the central macula in eyes with non-central GA.

At ARVO 2024, Roger Goldberg, MD explores the greater reductions in hard exudates achieved with faricimab than aflibercept in eyes with DME.

At ARVO 2024, Deepayan Kar, MD, PhD, describes the potential of measuring contrast sensitivity function using a novel gaze tracking-based VR headset in AMD.

Dolly Chang, MD, PhD, describes results from an exploratory analysis on the long-term impact of rapid fluid reduction on outcomes in DME.

Daniel Su, MD describes the promise of APX3330 for delaying or preventing diabetic retinopathy progression in a post-hoc analysis of the ZETA-1 trial.

Disease characteristics in wet AMD at baseline were not linked to aflibercept 8 mg dosing interval extensions in the phase 3 PULSAR trial at 96 weeks.

Daniela Ferrara, MD, PhD described the key takeaways from the machine learning model's performance in predicting outcomes for various treatment durations of faricimab in DME.

Retina specialists and an AI screening tool trained to measure geographic atrophy agreed in a majority of cases, potentially expediting clinical trial enrollment and increasing consistency in measuring the disease.

At ARVO 2024, Ashkan Abbey, MD describes key data from the pivotal OAKS and DERBY, and the GALE extension trial over 3 years of pegcetacoplan treatment.

The anti-VEGF agent tarcocimab significantly improved diabetic retinopathy severity score compared with SHAM in a phase 3 study.

The phase 2 trial failed to show improvement of ≥2-DRSS levels with the vorolanib intravitreal insert in patients with non-proliferative diabetic retinopathy.

BI 764524 was well tolerated following intravitreal administration of single and multiple doses in the phase 1/2a trial, with signs pointing to early efficacy.

A nutritional supplement significantly improved the signs and symptoms of dry eye, including tear production and reduced ocular surface damage.

This month's review focuses on digital technology use in ophthalmology, the association between vision impairment and mental health, and public health impacts in eye care.

AEYE Health receives clearance for the first artificial intelligence solution to allow fully autonomous screening for diabetic retinopathy using a portable device.

Both vaccine type and period mediated the risk of uveitis after COVID-19 vaccination in patients with a history of the ocular inflammatory event.

TJ Chao and Kristine Kucera, PA’s share their insights into the patient experience with oral systemic agents for plaque psoriasis.

Physician assistants TJ Chao and Kristine Kucera share their knowledge on which patients make good candidates for TYK2 inhibitors.

Areas with socioeconomic disadvantage often face concentrated poverty, poor walkability, and few healthcare facilities, creating challenges in eye care follow-up.

Eyenovia assessed the duration of effect of the lowest deliverable dose of tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5% in a phase 4 study.

Article intelligence chatbots, including ChatGPT and Bard, varied in accuracy, comprehensiveness, and readability on glaucoma questions adapted from patient brochures.